New approaches to small cell lung cancer therapy : from the laboratory to the clinic
AffiliationPerlmutter Cancer Center, New York University Langone Health, New York, NY, USA
MetadataShow full item record
AbstractSmall cell lung cancer patient outcomes have not yet been significantly impacted by the revolution in precision oncology, primarily due to a paucity of genetic alterations in actionable driver oncogenes. Nevertheless, systemic therapies that include immunotherapy are beginning to show promise in the clinic. While these results are encouraging, many patients do not respond to or rapidly recur after current regimens, necessitating alternative or complementary therapeutic strategies. In this review, we discuss ongoing investigations into the pathobiology of this recalcitrant cancer and the therapeutic vulnerabilities that are exposed by the disease state. Included within this discussion is a snapshot of the current biomarker and clinical trial landscapes for small cell lung cancer. Finally, we identify key knowledge gaps that should be addressed in order to advance the field in pursuit of reduced small cell lung cancer mortality. This review largely summarizes work presented at the Third Biennial IASLC Small Cell Lung Cancer Meeting.
CitationPoirier JT, George J, Owonikoko TK, Berns A, Brambilla E, Byers LA, et al. New approaches to small cell lung cancer therapy : from the laboratory to the clinic. J Thorac Oncol. 2020.
JournalJournal of Thoracic Oncology
- The Epithelial Sodium Channel (αENaC) Is a Downstream Therapeutic Target of ASCL1 in Pulmonary Neuroendocrine Tumors.
- Authors: He M, Liu S, Gallolu Kankanamalage S, Borromeo MD, Girard L, Gazdar AF, Minna JD, Johnson JE, Cobb MH
- Issue date: 2018 Apr
- Rationale for chemotherapy, immunotherapy, and checkpoint blockade in SCLC: beyond traditional treatment approaches.
- Authors: Spigel DR, Socinski MA
- Issue date: 2013 May
- Small cell lung cancer (SCLC): no treatment advances in recent years.
- Authors: Koinis F, Kotsakis A, Georgoulias V
- Issue date: 2016 Feb
- Co-expression network analysis identifies Spleen Tyrosine Kinase (SYK) as a candidate oncogenic driver in a subset of small-cell lung cancer.
- Authors: Udyavar AR, Hoeksema MD, Clark JE, Zou Y, Tang Z, Li Z, Li M, Chen H, Statnikov A, Shyr Y, Liebler DC, Field J, Eisenberg R, Estrada L, Massion PP, Quaranta V
- Issue date: 2013
- ASCL1 is a lineage oncogene providing therapeutic targets for high-grade neuroendocrine lung cancers.
- Authors: Augustyn A, Borromeo M, Wang T, Fujimoto J, Shao C, Dospoy PD, Lee V, Tan C, Sullivan JP, Larsen JE, Girard L, Behrens C, Wistuba II, Xie Y, Cobb MH, Gazdar AF, Johnson JE, Minna JD
- Issue date: 2014 Oct 14